FOSTER CITY, Calif. (AP) — Biologic drugmaker Gilead Sciences Inc.
has halted several patient studies of its cancer drug, Zydelig, because
of increased risk of death and serious side effects.
The company told The Associated Press the "adverse events" were spotted during an ongoing review of late-stage testing in patients with chronic lymphocytic leukemia, a blood cancer, and patients with relapsed non-Hodgkin's lymphoma, a cancer of the infection-fighting lymphatic system.
Nathan Kaiser, a spokesman for the Foster City, California, company, wouldn't disclose details, including how many patients died or suffered serious side effects.
"We are conducting a comprehensive review of all ongoing studies and
are consulting with regulatory authorities," Kaiser wrote in an email
Tuesday.
The company told The Associated Press the "adverse events" were spotted during an ongoing review of late-stage testing in patients with chronic lymphocytic leukemia, a blood cancer, and patients with relapsed non-Hodgkin's lymphoma, a cancer of the infection-fighting lymphatic system.
Nathan Kaiser, a spokesman for the Foster City, California, company, wouldn't disclose details, including how many patients died or suffered serious side effects.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.